Key facts
- Neurowyzr’s last known valuation is $13.7M (Aug 2023).
- It has raised $5.4M; the latest was Later Stage VC in May 2025.
- Notable investors include MedTech Innovator, Keiretsu Forum, Surge (Accelerator), SGInnovate, Jungle Ventures — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Neurowyzr
- ·The full record, as it builds
Funding rounds
No funding rounds for Neurowyzr are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Neurowyzr
Developer of neuroscience-based digital brain health technologies designed to support early detection, diagnosis, therapy, monitoring, and prevention of brain decline. The company offers digital medical cognitive assessment tools and other neuroscience-driven applications for brain health, enabling healthcare providers and individuals to evaluate cognitive function, identify decline earlier, and support ongoing brain-health management.
- Sector
- Healthcare
- HQ
- Singapore, Singapore
- Founded
- 2019
- Employees
- 25
- Website
- neurowyzr.com/
- Ownership
- Privately Held (backing)
Neurowyzr doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Neurowyzr shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Neurowyzr in its N-PORT filings yet. We sweep new filings monthly.